- Home
- RIGL vs ACHV Comparison
RIGL vs ACHV Comparison
Compare RIGL & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ACHV
- Stock Information
- Founded
- RIGL 1996
- ACHV N/A
- Country
- RIGL United States
- ACHV Canada
- Employees
- RIGL N/A
- ACHV N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RIGL Health Care
- ACHV Health Care
- Exchange
- RIGL Nasdaq
- ACHV Nasdaq
- Market Cap
- RIGL 271.5M
- ACHV 159.0M
- IPO Year
- RIGL 2000
- ACHV N/A
- Fundamental
- Price
- RIGL $15.14
- ACHV $5.05
- Analyst Decision
- RIGL Buy
- ACHV Strong Buy
- Analyst Count
- RIGL 4
- ACHV 4
- Target Price
- RIGL $31.13
- ACHV $15.50
- AVG Volume (30 Days)
- RIGL 220.7K
- ACHV 118.6K
- Earning Date
- RIGL 11-05-2024
- ACHV 11-07-2024
- Dividend Yield
- RIGL N/A
- ACHV N/A
- EPS Growth
- RIGL N/A
- ACHV N/A
- EPS
- RIGL N/A
- ACHV N/A
- Revenue
- RIGL $130,201,000.00
- ACHV N/A
- Revenue This Year
- RIGL $38.26
- ACHV N/A
- Revenue Next Year
- RIGL $24.21
- ACHV N/A
- P/E Ratio
- RIGL N/A
- ACHV N/A
- Revenue Growth
- RIGL 7.48
- ACHV N/A
- 52 Week Low
- RIGL $7.10
- ACHV $3.03
- 52 Week High
- RIGL $17.30
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- RIGL 52.41
- ACHV 61.03
- Support Level
- RIGL $14.58
- ACHV $4.85
- Resistance Level
- RIGL $15.87
- ACHV $5.19
- Average True Range (ATR)
- RIGL 0.74
- ACHV 0.20
- MACD
- RIGL -0.19
- ACHV 0.00
- Stochastic Oscillator
- RIGL 24.67
- ACHV 65.67
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.